The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 01, 2020
Filed:
Sep. 18, 2018
Applicant:
Trustees of Boston University, Boston, MA (US);
Inventors:
Nelson Ruiz-Opazo, Westwood, MA (US);
Victoria L. M. Herrera, Westwood, MA (US);
Assignee:
TRUSTEES OF BOSTON UNIVERSITY, Boston, MA (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 9/51 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); C12N 9/78 (2006.01); C12N 9/50 (2006.01); C12N 9/08 (2006.01); C12N 9/16 (2006.01); A61P 11/00 (2006.01); A61P 9/12 (2006.01);
U.S. Cl.
CPC ...
A61K 39/001109 (2018.08); A61K 9/51 (2013.01); A61P 9/12 (2018.01); A61P 11/00 (2018.01); A61P 35/00 (2018.01); C07K 16/2863 (2013.01); C12N 9/0065 (2013.01); C12N 9/16 (2013.01); C12N 9/50 (2013.01); C12N 9/78 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C12Y 111/02002 (2013.01); C12Y 301/21001 (2013.01); C12Y 304/21037 (2013.01); C12Y 304/24007 (2013.01); C12Y 305/03001 (2013.01); C12Y 305/04004 (2013.01);
Abstract
Described herein are methods and compositions relating to methods of inhibiting neutrophils, e.g., inhibiting NET release or NETosis, by means of a DEspR inhibitor, e.g., an anti-DEspR antibody reagent. In some embodiments, the methods can relate to the treatment of a disease, e.g., cancer or a disease wherein neutrophils; NETs; or NETosing or NETting neutrophils contribute to pathogenesis, chronicity, or worsening of disease. In some embodiments, the DEspR inhibitor can be a bi-specific reagent or an antibody-drug conjugate.